Vertex Pharmaceuticals (VRTX) EBT Margin (2009 - 2026)

Vertex Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 41.95% for Q1 2026.

• In Q1 2026, EBT Margin rose 1558.0% year-over-year to 41.95%; the TTM figure through Mar 2026 stood at 42.28% (up 4498.0% YoY), while the FY2025 annual figure was 38.69%, up 3643.0% from the prior year.
• EBT Margin was 41.95% for Q1 2026 at Vertex Pharmaceuticals, up from 41.72% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 50.4% in Q3 2022 to a low of 128.18% in Q2 2024.
• Historically, EBT Margin has averaged 33.21% across 5 years, with a median of 44.16% in 2024.
• The sharpest annual moves came in 2024 and 2025: EBT Margin plunged 17477 bps in 2024, then surged 17146 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 46.76% in 2022, then dropped by 3 bps to 45.58% in 2023, then declined by 14 bps to 39.03% in 2024, then grew by 7 bps to 41.72% in 2025, then advanced by 1 bps to 41.95% in 2026.
• The last three EBT Margin figures came in at 41.95% (Q1 2026), 41.72% (Q4 2025), and 42.22% (Q3 2025), per Business Quant data.